-
Low-Dose Staphylococcal Enterotoxin C2 Mutant Maintains Bon
ADVANCED SCIENCEResearch ArticleLow-Dose Staphylococcal Enterotoxin C2 Mutant MaintainsBone Homeostasis via Regulating Crosstalk between BoneFormation and Host T-Cell Effector ImmunityHaixing Wang, Si
2023-12-14 191
-
Staphylococcal enterotoxin C2 promotes osteogenesis.....
While SEC2 was found to have no effect on rat MSCs proliferation, it promoted the osteoblast differentiation of rat MSCs. In the rat femoral fracture model, the local administration of SEC2 accelerated fracture healing by increasing fracture callus volumes, bone volume over total volume (BV/TV), and biomechanical re...
2020-12-02 300
-
Staphylococcal enterotoxin C2 expedites bone consolidation d
Staphylococcal enterotoxin C2 expedites bone consolidation during distraction osteogenesis
2020-12-01 358
-
An engineered superantigen SEC2 exhibits promising antitumor
An engineered superantigen SEC2 exhibits promising antitumor activity and low toxicityAbstract Recent studies suggested that the histidine residues at 118 and 122 play an important role for the t
2020-12-01 322
-
HAS : A Novel Anti-cancer Drug Prepared from SEC Superantige
HAS is a novel anti-cancer drug developed by Xiehe Bio- pharmaceutical Company, Shenyang,China. It is prepared and processed from the filtrate of Staphylococcus aureus culture. The active component contained in it has been shown to be a SEC superantigen that is a metabolite of the culture. This superantigen is marked b...
2020-02-20 300
-
Staphylococcal enterotoxin microbial superantigens
07ba934228a55d6a2fa99e7630f6e6d0.pdf
2019-03-10 313
-
Long-term results of a phase II clinical trial of superantig
716e2ad73af71c2b1eb93269e02c30ba.pdf
2019-03-10 253
-
Research advances on immunopharmacology and cancer therapy o
fea2a25a77079101f32582e566aea70d.pdf
2019-03-10 376
-
Clinical observation on pericardial effusion in patients wit
8797f25c93c169ce18d610fe066b8e80.pdf
2019-03-10 234
-
The treatment effects and mechanism of highly agglutinative
5a58aa0a6eb426907480f7aff53d7e55.pdf
2019-03-10 239